674 reports of this reaction
1.9% of all INTERFERON BETA 1B reports
#17 most reported adverse reaction
HYPOAESTHESIA is the #17 most commonly reported adverse reaction for INTERFERON BETA 1B, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 674 FDA adverse event reports linking INTERFERON BETA 1B to HYPOAESTHESIA. This represents approximately 1.9% of all 36,175 adverse event reports for this drug.
Patients taking INTERFERON BETA 1B who experience hypoaesthesia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOAESTHESIA is a less commonly reported adverse event for INTERFERON BETA 1B, but still significant enough to appear in the safety profile.
In addition to hypoaesthesia, the following adverse reactions have been reported for INTERFERON BETA 1B:
The following drugs have also been linked to hypoaesthesia in FDA adverse event reports:
HYPOAESTHESIA has been reported as an adverse event in 674 FDA reports for INTERFERON BETA 1B. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOAESTHESIA accounts for approximately 1.9% of all adverse event reports for INTERFERON BETA 1B, making it a notable side effect.
If you experience hypoaesthesia while taking INTERFERON BETA 1B, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.